| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 4, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 4, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
10-Q - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
EFFECT - SenesTech, Inc. (0001680378) (Filer)
PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye
PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.
Record Revenue and Margin Performance PHOENIX, Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), the leader in fertility control to manage animal pest populations and the only manufacturer of commercial and consumer available EPA-registered Rat Birth Control® products today announced financial results for the third quarter of 2024. Recent Highlights Revenues of $1.4 million in the first nine months of 2024, an increase of 51% compared to the same period of 2023.Gross margin percentages improved to 65% during Q3 2024 compared to
Significantly Expanding Market Reach PHOENIX, Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a leader in fertility control solutions for managing animal pest populations, is excited to announce a significant expansion in the distribution of its groundbreaking rodent birth control product. Evolve™ Rat and Evolve™ Mouse are now available on Walmart Marketplace, one of the largest and most trusted eCommerce platforms in the world. SenesTech developed its proprietary technology for managing rat and mouse populations—through fert
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, Nov. 5, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its third quarter 2024, ended September 30, 2024, after the market close on Tuesday, November 12, 2024. The Company has scheduled a conference call that same day, Tuesday, November 12, 2024, at 5:00 pm ET, to review the results. Third Quarter 2024 Conference Call Details Date and Time: Tuesday, November 12, 2024, at 5:00 pm ET Call-in Information: Interested parties can access th
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
Record Revenue and Margin Performance PHOENIX, Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), the leader in fertility control to manage animal pest populations and the only manufacturer of commercial and consumer available EPA-registered Rat Birth Control® products today announced financial results for the third quarter of 2024. Recent Highlights Revenues of $1.4 million in the first nine months of 2024, an increase of 51% compared to the same period of 2023.Gross margin percentages improved to 65% during Q3 2024 compared to
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, Nov. 5, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its third quarter 2024, ended September 30, 2024, after the market close on Tuesday, November 12, 2024. The Company has scheduled a conference call that same day, Tuesday, November 12, 2024, at 5:00 pm ET, to review the results. Third Quarter 2024 Conference Call Details Date and Time: Tuesday, November 12, 2024, at 5:00 pm ET Call-in Information: Interested parties can access th
Record Revenue and Margin Performance PHOENIX, Aug. 8, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the second quarter of 2024. Recent Highlights Record revenues of $874,000 in the first half of 2024, an increase of 62% compared to the first half of 2023.Gross margin percentages improved to 54% during Q2 2024 compared to 47% in Q1 2024
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G - SenesTech, Inc. (0001680378) (Subject)